Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis

Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis

<p>Abstract</p> <p>Background</p> <p>The development of an effective vaccine against visceral leishmaniasis (VL) caused by <it>Leishmania donovani </it>is an essential aim for controlling the disease. Use of the right adjuvant is of fundamental importance in...

Full description

Bibliographic Details
Main Authors:	Bhowmick Sudipta, Ravindran Rajesh, Das Amrita, Ali Nahid
Format:	Article
Language:	English
Published:	BMC 2010-06-01
Series:	BMC Microbiology
Online Access:	http://www.biomedcentral.com/1471-2180/10/181

Similar Items

Combining cationic liposomal delivery with MPL-TDM for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protection.
by: Amrita Das, et al.
Published: (2014-08-01)

Correction: Combining Cationic Liposomal Delivery with MPL-TDM for Cysteine Protease Cocktail Vaccination against Leishmania donovani: Evidence for Antigen Synergy and Protection.
by: Amrita Das, et al.
Published: (2015-10-01)

Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis.
by: Sudipta Bhowmick, et al.
Published: (2009-06-01)

Different liposomal amphotericin B formulations for visceral leishmaniasis
by: Thomas P C Dorlo, et al.
Published: (2014-08-01)

Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.
by: Saumyabrata Mazumder, et al.
Published: (2011-12-01)

Immunogenicity and protection effects of cationic liposome containing imiquimod adjuvant on leishmaniasis in BALB/c mice
by: Ahmad Mehravaran, et al.
Published: (2019-08-01)

Formulation and development of cationic liposomes as adjuvants for subunit protein vaccinese
by: Henriksen, Malou
Published: (2011)

Different liposomal amphotericin B formulations for visceral leishmaniasis–Author's reply
by: Nilima Kshirsagar
Published: (2014-08-01)

Antileishmanial activity of fullerol and its liposomal formulation in experimental models of visceral leishmaniasis
by: Guilherme S. Ramos, et al.
Published: (2021-02-01)

Single-dose liposomal amphotericin B for visceral leishmaniasis
by: Nilima A Kshirsagar
Published: (2014-04-01)

Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis
by: Abdus Sabur, et al.
Published: (2018-01-01)

Formulation and characterisation of cationic liposomal adjuvants for the delivery of a promising subunit c
by: Hussain, Mohammed
Published: (2011)

Testicular stereological and histological changes in an experimental murine model of visceral leishmaniasis
by: Erfan Yarahmadi, et al.
Published: (2019-10-01)

MPL Adjuvant Contains Competitive Antagonists of Human TLR4
by: Yi-Qi Wang, et al.
Published: (2020-10-01)

Design and development of cationic liposomes as DNA vaccine adjuvants
by: Moghaddam, Behfar
Published: (2013)

Superimposed visceral leishmanial infection aggravates response to Heligmosomoides polygyrus
by: M. E. González-Sánchez, et al.
Published: (2018-07-01)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
by: Gloria Morizot, et al.
Published: (2016-01-01)

Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis
by: Want MY, et al.
Published: (2017-03-01)

Studies on the immunological control of murine visceral leishmaniasis
by: McFarlane, Emma
Published: (2007)

The role of B lymphocytes in murine visceral leishmaniasis
by: Smelt, Sara Catherine
Published: (1998)

Sertraline Delivered in Phosphatidylserine Liposomes Is Effective in an Experimental Model of Visceral Leishmaniasis
by: Maiara Maria Romanelli, et al.
Published: (2019-10-01)

Single-dose liposomal amphotericin B: an effective treatment for visceral leishmaniasis
by: Prabhat Kumar Sinha, et al.
Published: (2014-01-01)

Immunity to Visceral Leishmaniasis
by: Nahid Ali, et al.
Published: (2012-01-01)

Liposomes containing the imiquimod adjuvant as a vaccine in the cutaneous leishmaniasis model
by: Ahmad Mehravaran, et al.
Published: (2020-01-01)

The involvement of TLR2 and TLR4 in cytokine and nitric oxide production in visceral leishmaniasis patients before and after treatment with anti-leishmanial drugs.
by: Mariana Gatto, et al.
Published: (2015-01-01)

Expression pattern of the thrombopoietin receptor (Mpl) in the murine central nervous system
by: Hoffmann Olaf, et al.
Published: (2010-07-01)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
by: Andrew A Voak, et al.
Published: (2021-03-01)

Phenotypical Characterization of Spleen Remodeling in Murine Experimental Visceral Leishmaniasis
by: Caroline Vilas Boas de Melo, et al.
Published: (2020-04-01)

Efficacy of Spironolactone Treatment in Murine Models of Cutaneous and Visceral Leishmaniasis
by: Valter Viana Andrade-Neto, et al.
Published: (2021-04-01)

Visceral leishmaniasis with pleural effusion in an immunocompetent patient
by: Senjuti Dasgupta, et al.
Published: (2014-01-01)

Genetically Modified Organisms and Visceral Leishmaniasis
by: NAHID eALI, et al.
Published: (2014-05-01)

Leishmanial abscess
by: Sandeep Arora, et al.
Published: (2017-01-01)

Leishmanial antigens in the diagnosis of active lesions and ancient scars of American tegumentary leishmaniasis patients
by: Armando Schubach, et al.
Published: (2001-10-01)

Hematological profiles of visceral leishmaniasis patients before and after treatment of anti-leishmanial drugs at University of Gondar Hospital; Leishmania Research and Treatment Center Northwest, Ethiopia
by: Elias Shiferaw, et al.
Published: (2021-09-01)

Biological Activity of Coumarin Derivatives as Anti-Leishmanial Agents.
by: Vineetha Mandlik, et al.
Published: (2016-01-01)

Testicular stereological and histological changes in an experimental murine model of visceral leishmaniasis
by: Yarahmadi E, et al.
Published: (2019-10-01)

One approach to assess the liver responses in murine listeriosis and visceral leishmaniasis
by: G. Milon, et al.
Published: (1988-11-01)

Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis.
by: Steven C Derrick, et al.
Published: (2012-01-01)

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis
by: Gert-Jan Wijnant, et al.
Published: (2018-08-01)

Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.
by: Else Marie Agger, et al.
Published: (2008-01-01)

Cannot write session to /tmp/vufind_sessions/sess_midubj3crqeq7bcps4k5q8guk1